Introduction
============

Gastro-esophageal reflux (GERD) is defined as the reflux of gastric contents into the esophagus leading to reflux symptoms sufficient to affect patient well-being and/or cause complications ([@b58]). Population-based studies suggest that heartburn is a very common symptom in the general population with a prevalence of 10%--20% in the Western world but far from all are consulters. However, in Asia the prevalence of GERD-like symptoms is lower and has been reported to be less than 5% ([@b6]; [@b42]). When traditional endoscopy is used, GERD can be subdivided into reflux esophagitis (or erosive GERD) and endoscopy-negative reflux disease (or non-erosive reflux disease, NERD) ([@b42]; [@b58]). About 50% of patients with the disease have a normal endoscopy in referral centers ([@b23]; [@b26]), but in primary care the occurrence of esophagitis is lower ([@b58]). Erosive GERD has been associated with complications such as esophageal strictures and Barrett's esophagus ([@b58]).

The proton pump inhibitors (PPIs) are substituted benzimidazoles administered as enteric-coated tablets or capsules that pass through the stomach and are absorbed in the duodenum. They act on the proton pump molecule on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion ([@b18]). Esomeprazole is the latest PPI and was developed as the S-isomer of omeprazole as an improvement in its pharmacokinetic properties ([@b18]; [@b29]). PPIs are the drugs of choice in the treatment of GERD ([@b42]).

Esomeprazole is considered to have a somewhat higher potency in acid inhibition than other PPIs ([@b18]; [@b29]; [@b19]). However, previous reports have reported variable results in comparing its efficacy in healing erosive GERD, in maintenance therapy of healed erosive GERD, and in therapy of NERD compared with other PPIs. Some systematic reviews and meta-analyses have been published on the efficacy of esomeprazole in the therapy of erosive GERD ([@b30]; [@b56]; [@b10]; [@b16]). The aim of the current systematic review was to provide an update on the efficacy of esomeprazole in acid suppression, in the acute and maintenance therapy of erosive GERD and NERD as well as in improving health-related quality of life (QoL) in GERD. Comparison with other PPIs in this context was also undertaken.

Data selection
==============

We performed a structured electronic search of PuBMed to identify English-language, randomized clinical trials from 2000 to 2006 comparing esomeprazole vs alternative PPIs in the treatment of GERD. The bibliography of systematic reviews and meta-analyses performed comparing the efficacy of esomeprazole vs other PPIs in GERD was searched manually for references not found by the strategy described above. Abstracts from presentations at conferences, animal studies, or data from the manufacturers not published as full-text articles were not included. A review of the literature on esomeprazole and Barrett's esophagus or extraesophageal manifestations of GERD was beyond the scope of this article.

Acid suppression
================

Although investigators agree that GERD is associated with dysmotility and results from an imbalance between normal defensive factors such as esophageal clearance, lower esophageal sphincter tone, and aggressive factors such as acid and pepsin, it has become increasingly clear that the key to controlling symptoms and to healing esophagitis is decreasing the duration of exposure to the acidic refluxate ([@b22]). The duration of esophageal exposure to a refluxate with a pH of 4.0 or less has been shown to be correlated to mucosal injury and to a reduced ability of the injured mucosa to proliferate and heal ([@b2]; [@b22]). Controlling GERD symptoms and healing erosive GERD can be best achieved by increasing the gastric pH to 4.0 or above for as long a duration as possible ([@b2]; [@b22]). Furthermore, it has been suggested that in patients with more severe grades of esophagitis, there are abnormally high levels of nocturnal acid exposure ([@b2]). Also, ulcerative esophagitis, esophageal strictures, and Barrett's esophagus are characterized by high levels of supine nocturnal percentage acid reflux time ([@b13]), indicating that control of nocturnal acid secretion is important.

PPIs reduce gastric acid secretion by inhibiting activity of the gastric H^+^/K^+^-ATPase. They are protonated in the acidic gastric environment to active forms, which irreversibly bind to the H^+^/K^+^-ATPase and inactivate it ([@b22]; [@b18]; [@b19]). As PPIs block the last step in the pathway to gastric acid secretion, they are effective in both basal and stimulated acid secretion ([@b22]; [@b19]).

The effects of esomeprazole on gastric acidity
----------------------------------------------

Recently, acid control with esomeprazole has been compared with that of other PPIs in several cross-over studies in either patients with GERD or in healthy individuals. As shown in [Table 1](#tbl1){ref-type="table"}, all studies showed that esomeprazole 40 mg od was more effective in maintaining intragastric pH at 4.0 or lower compared with all other PPIs given at standard doses. The same studies demonstrated that esomeprazole 40 mg od is superior to all other PPIs at standard doses in terms of achieving higher 24-hour median intragastric pH and in terms of the number of patients achieving intragastric pH ≥4.0 for at least 12 hours per day. Nocturnal pH was measured in one of these studies, comparing esomeprazole 40 mg with pantoprazole 40 mg bd ([@b40]). During night-time the proportion of time with intragastric pH \>4.0 was 85.4% with esomeprazole and 63.6% with pantoprazole (p = 0.0001). Nocturnal acid breakthrough, defined as intragastric pH \<4.0 for at least one consecutive hour between 10 pm and 6 am, was observed in 26.7% of subjects receiving esomeprazole and in 73.3% of those receiving pantoprazole (p = 0.009) ([@b40]). Data on the effect of esomeprazole on nocturnal pH in comparison with other PPIs are otherwise largely lacking.

###### 

Gastric acidity, expressed as the percentage of time with intragastric pH \>4.0 on day 5 in individuals treated with esomeprazole, omeprazole, pantoprazole, and rabeprazole in cross-over randomized pharmacodynamic studies

  Reference   Study design                           Patient/individual selection   PPIs compared                                     Number of individuals   Percentage of time with intragastric pH \>4.0
  ----------- -------------------------------------- ------------------------------ ------------------------------------------------- ----------------------- -----------------------------------------------
  [@b38]      Double-blind, randomized, cross-over   GERD symptoms                  Eso40 vs eso20 vs ome 20 od                       38                      69.8% vs 53.0 vs 43.7% p \< 0.01
  [@b48]      Open-label, randomized, cross-ove      GERD symptoms                  Eso40 vs ome 40 od                                130                     68.4% vs 62.0%, p \< 0.001
  [@b60]      Open-label, randomized, cross-over     Healthy volunteers             Eso40 vs lan30 od                                 24                      65% vs 53%, p \< 0.001
  [@b60]      Open-label, randomized, cross-over     Healthy volunteers             Eso40 vs rabe20 od                                23                      61% vs 45.1%, p = 0.005
  [@b41]      Open-label, randomized, cross-over     GERD symptoms                  Eso40 vs lan30 vs ome20 vs panto40 vs rabe20 od   34                      58.4% vs 47% vs 49.1 vs 50.5%, p \< 0.001
  [@b49]      Open-label, randomized cross-over      GERD symptoms                  Eso40 vs lan30 od                                 36                      57.5% vs 44.6%, p \< 0.0001
  [@b49]      Open-label, randomized, cross-over     GERD symptoms                  Eso40 vs ome20 od                                 38                      70% vs 43.8%, p \< 0.0001
  [@b49]      Open-label, randomized, cross-over     GERD symptoms                  Eso40 vs panto40 od                               32                      67.1% vs 45%, p \< 0.001
  [@b49]      Open-label, randomized, cross-over     GERD symptoms                  Eso40 vs rabe20 od                                35                      59.6% vs 44.6%, p \< 0.0001
  [@b40]      Single-blind, randomized, cross-over   Healthy volunteers             Eso40 vs panto bd                                 30                      85.4% vs 63.6%, p = 0.0001
  [@b25]      Open-label, randomized, cross-over     GERD symptoms 2005             Eso40 bd vs lan30 bd vs eso40 od vs lan30 od      45                      81.3% vs 65.4% vs 60.1% vs 51.3% p \< 0.05

**Abbreviations:** Eso, esomeprazole; GERD, gastroesophageal reflux disease; lan, lansoprazole; ome, omeprazole; PPI, proton-pump inhibitor; panto, pantoprazole; rabe, rabeprazole.

In certain situations, it is reasonable to use higher than approved doses of PPIs, often divided in two doses. These include a diagnostic trial for noncardiac chest pain, empiric treatment trial for supraesophageal symptoms of GERD, cases of partial response to standard dose therapy, cases with breakthrough symptoms, GERD patients with severe esophageal dysmotility, and Barrett's esophagus ([@b7]). A recent double-blind, randomized, cross-over study investigated the 24-hour intragastric pH profile of esomeprazole 40 mg bd vs 20 mg bd vs 40 mg od in 25 healthy volunteers ([@b28]). Esomeprazole 40 mg bd provided a mean time of 19.2 hours with intragastric pH \>4.0 (80.1% of a 24-hour time period, 95% confidence interval (CI) 74.5%--85.7%) vs 14.2 hours with 40 mg od (59.2%, 95% CI 53.7%--64.7%) and 17.5 hours with 20 mg bd (73.0%, 95% CI 67.4%--78.5%). The percentage of time of a 24-hour period that pH remained \>4.0 was significantly higher with the esomeprazole bd dosing regimens compared to the 40 mh od regimen during the supine (sleeping) portion of the monitoring period (83.7% (95% CI 74.9%--92.4%) for esomeprazole 40 mg bd vs 79.2% (95% CI 70.5%--87.9%) for esomeprazole 20 mg bd vs 57.9% (95% CI 49.0%--66.9%) for esomeprazole 40 mg od ([@b28]). Esomeprazole 40 mg bd has also been shown to be superior to pantoprazole 40 mg bd and lansoprazole 30 mg bd in maintaining intragastric pH at 4.0 or lower ([Table 1](#tbl1){ref-type="table"}). These data indicate that twice-daily dosing of omeprazole provides significantly greater acid suppression than once-daily dosing and may, therefore, be a reasonable consideration for patients requiring greater acid-suppression for GERD.

The effects of esomeprazole on esophageal acidity
-------------------------------------------------

Two studies have assessed the effect of esomeprazole on intraesophageal pH profiles compared to other PPIs. In a double-blind, randomized, cross-over study in 35 patients with GERD symptoms, esomeprazole 40 mg od was compared with pantoprazole 40 mg od as to their effects on intraesophageal pH ([@b52]). At baseline the median percentage of total time with pH \<4.0 was 20.1% in the esomeprazole and 21.3% in the pantoprazole group. After 7 days of repeated administration, this time was reduced to 0.9% and 2.6% respectively, and the mean within-subject differences in mean 24-hour pH values between pre- and post-treatment values were 19.2% and 18.7% respectively. The Hodges-Lehmann estimate for the mean within-subjects differences in mean 24-hour pH between pre- and post-treatment values for the two PPIs was 2.86% and the corresponding 90% CI was within the equivalence range set at ± 10% (90% CI −2.27; 7.07) ([@b52]). In another open-label randomized study, esomeprazole 40 mg od was compared with lansoprazole 30 mg od in 30 patients with complicated GERD ([@b14]). Normalization of total and supine nocturnal esophageal acid exposure was achieved in 75% vs 28% (p = 0.026) and 93% vs 50% (p = 0.012) of patients in the esomeprazole and the lansoprazole group, respectively ([@b14]).

Erosive GERD
============

Randomized trials evaluating the role of esomeprazole in healing of erosive GERD or maintenance therapy of healed erosive GERD were reviewed.

Healing of erosive GERD
-----------------------

Several clinical trials have compared esomeprazole with other PPIs in healing of erosive GERD ([Table 2](#tbl2){ref-type="table"}). Studies reported in [Table 2](#tbl2){ref-type="table"} had a similar double-blind, randomized design; they included intention-to-treat analyses of healing rates, and, as a secondary endpoint, evaluation of therapy effect on GERD symptoms. Also, all studies included patients who had endoscopy-confirmed erosive GERD at baseline. Follow-up endoscopy was performed at 4 weeks and at 8 weeks, except for one study in which patients underwent first follow-up endoscopy at 4 or 6 weeks and second follow-up endoscopy at 8 or 10 weeks ([@b15]). Although at least two randomized studies comparing esomeprazole with each of the other PPIs were identified, no comparative studies of esomeprazole vs rabeprazole in erosive GERD could be found.

###### 

Randomized trials evaluating the efficacy of esomeprazole vs other proton-pump inhibitors in healing erosive GERD

  Reference   Study design               Number of patients   PPIs compared                Healing rates intention-to-treat analysis                                     
  ----------- -------------------------- -------------------- ---------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------
  [@b27]      Double-blind, randomized   1960                 Eso40 vs eso20 vs ome20 od   75.9% vs 70.5% vs 64.7%, p \< 0.05 for eso40 vs p = 0.09 for eso20 vs ome20   94.1% vs 89.9% vs 86.9%, p \< 0.05 for all comparisons
  [@b47]      Double-blind, randomized   2425                 Eso40 vs ome20 od            81.7% vs 68.7%, p \< 0.001                                                    93.7% vs 84.2%, p \< 0.001
  [@b50]      Double-blind, randomized   1148                 Eso40 vs ome20 od            68.2% vs 66.3%, p = 0.385                                                     87% vs 85.8, p = 0.552
  [@b4]       Double-blind, randomized   5241                 Eso40 vs lan30 od            79.4% vs 75.1%, p \< 0.05                                                     92.6% vs 88.8%, p \< 0.0001
  [@b21]      Double-blind, randomized   284                  Eso40 vs lan30 od            78.3% vs 77%, p \> 0.05                                                       91.4% vs 89.1, p \> 0.05
  [@b11]      Double-blind, randomized   1001                 Eso40 vs lan30 od            55.8% vs 47.5%, p = 0.005                                                     82.4% vs 77.5%, p = 0.005
  [@b15]      Double-blind, randomized   227                  Eso40 vs panto40 od          72% vs 74%, p \> 0.05[a](#tf2-1){ref-type="table-fn"}                         92% vs 90%, p \> 0.05[b](#tf2-2){ref-type="table-fn"}
  [@b34]      Double-blind, randomized   3170                 Eso40 vs panto40 od          81% vs 74.5%, p \< 0.001                                                      92% vs 95.5%, p \< 0.001

Healing rates regarding the first follow-up visit at 4 or 6 weeks in this study

Healing rates at the second follow-up visit at 8 or 10 weeks in this study

**Notes:** No randomized studies comparing esomeprazole with rabeprazole for healing erosive GERD were found.

**Abbreviations:** Eso, esomeprazole; ome, omeprazole; lan, lansoprazole; panto, pantoprazole; PPI, proton-pump inhibitor.

Five out of 8 studies showed that esomeprazole 40 mg od achieves better healing rates of erosive esophagitis after 4 and 8 weeks of treatment compared with omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od ([Table 1](#tbl1){ref-type="table"}). In these trials a total of 13,797 patients with erosive GERD were included. The greater efficacy of esomeprazole over omeprazole, lansoprazole, or pantoprazole was consistent when adjusted for baseline severity of esophagitis according to the Los-Angeles classification. Furthermore, all of these studies showed that esomeprazole 40 mg od is more effective than omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od in providing resolution of GERD-associated symptoms ([@b27]; [@b47]; [@b4]; [@b11]; [@b34]). Interestingly, all these studies were supported by the manufacturer of esomeprazole.

However, 3/8 comparative studies, in which a total of 1659 patients were included, showed that there were no statistically significant differences in 4- or 8-week healing rates between esomeprazole 40 mg od and omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od. One of these studies showed that healing rates with esomeprazole were significantly higher than those with omeprazole at weeks 4 (60.8% vs 47.9%, p = 0.02) and 8 (88.4% vs 77.5%, p = 0.007) in patients with moderate to severe (Los Angeles grade C or D) erosive esophagitis at baseline but were not significantly different for patients with mild (Los Angeles grade A or B) erosive esophagitis ([@b50]). These studies reported similar efficacy of esomeprazole compared to omeprazole, lansoprazole, or pantoprazole in GERD-related symptoms ([@b21]; [@b15]; [@b50]). One out of three of these studies was supported by the manufacturer of esomeprazole, showing some benefits of esomeprazole for patients with more severe esophagitis ([@b50]). The other two were supported by the manufacturers of lansoprazole, showing no difference between lansoprazole and esomeprazole ([@b21]), and by the manufacturer of pantoprazole, showing no difference between pantoprazole and esomeprazole ([@b15]). Equivalence of esomeprazole 40 mg and pantoprazole 40 mg od in treating GERD-related symptoms in patients with erosive GERD was also reported in a double-blind randomized study in which 217 patients with esophagitis were included ([@b51]). In this trial no follow-up endoscopic evaluation was performed and, thus, no data on healing rates could be calculated ([@b51]).

*Helicobacter pylori* infection has been shown to elevate the intragastric pH achieved by PPIs ([@b59]; [@b35]). In a study with pantoprazole, it has also been proposed that this increased efficacy of PPIs in *H. pylori*-infected patients may be associated with improved symptom control and more rapid healing of the esophagitis ([@b20]). Furthermore, *H. pylori* eradication has been reported to be a predictor of failure in the treatment of GERD with omeprazole 20 mg od ([@b61]) but this finding was not reproduced in another study ([@b31]). A recent review on this topic concluded that at present it is unclear whether *H. pylori* should be eradicated in GERD patients ([@b5]). In all of the studies reviewed here *H. pylori* status was evaluated in the patients included. A significant effect of *H. pylori* infection was shown in one of the studies comparing esomeprazole 40 mg with pantoprazole 40 mg od with *H. pylori*-negative patients experiencing lower healing rates than in *H. pylori*-positive patients ([@b34]). No difference was observed in the efficacy of esomeprazole between *H. pylori*-negative and *H. pylori*-positive GERD patients in the studies where this was investigated ([@b27]; [@b47]; [@b4]; [@b15]; [@b11]; [@b34]; [@b50]). However, it should be taken into consideration that the effect of *H. pylori* status on healing of erosive esophagitis was only a secondary endpoint in these studies.

Five meta-analyses on the effect of different PPIs were identified ([@b9], [@b10]; [@b30]; [@b56]; [@b16]), three of which focused on the effect of different PPIs (including esomeprazole) in healing erosive esophagitis ([@b9], [@b10]; [@b16]). In a recent meta-analysis comparing the efficacy of PPIs in short-term use ([@b30]), two studies evaluating healing rates with esomeprazole 40 mg vs omeprazole 20 mg od were included ([@b27]; [@b47]). The authors concluded that esomeprazole was superior to omeprazole (relative risk, 1.18; 95% CI 1.14--1.23) ([@b30]). Another meta-analysis comparing the efficacy of PPIs in the management of GERD and peptic ulcer disease ([@b56]) included three studies comparing esomeprazole 40 mg od with either omeprazole 20 mg od ([@b27]; [@b47]) or lansoprazole 30 mg od ([@b4]). The authors concluded that esomeprazole was superior to both the PPIs with which it was compared in healing of erosive esophagitis and in speed of symptom relief ([@b56]). In a meta-analysis of the efficacy of PPIs in acute treatment of reflux esophagitis ([@b9]), three studies comparing esomeprazole 40 mg with omeprazole 20 mg od were included. Two of these were taken into consideration in the current review as well ([@b27]; [@b47]) but [@b9] also used data on file from the manufacturer of esomeprazole. They concluded that esomeprazole demonstrated higher healing rates than omeprazole at 4 weeks (relative risk 1.14; 95% CI 1.10--1.18) and 8 weeks (relative risk 1.08: 95% CI 1.05, 1.10) ([@b9]). Another meta-analysis by the same investigators comparing esomeprazole with other PPIs for the healing of erosive esophagitis ([@b10]) included all the randomized trials summarized in [Table 2](#tbl2){ref-type="table"}. The authors concluded that esomeprazole demonstrated higher healing rates compared with standard dose PPIs at 4 weeks (relative risk 0.92; 95% CI 0.90,0.94; p \< 0.00001) and at 8 weeks (relative risk 0.95; 95% CI 0.94.0.97; p \< 0.00001) ([@b10]). Lastly, a meta-analysis of randomized clinical trials comparing esomeprazole with other PPIs in healing erosive esophagitis ([@b16]), included 7 out of the 8 randomized studies summarized in [Table 2](#tbl2){ref-type="table"} ([@b27]; [@b47]; [@b4]; [@b21]; [@b15]; [@b11]; [@b34]) as well as data from the manufacturer of esomeprazole included in the product information (esomeprazole vs omeprazole 20 mg od) and a study published in abstract form (esomeprazole 40 mg vs omeprazole 40 mg od). The last two mentioned studies have not been published and could therefore potentially create a bias in this context. In comparing healing rates of erosive esophagitis at 4 and 8 weeks, the authors found a 10% (relative risk 1.10; 95% CI 1.05--1.15) and 5% (relative risk 1.05; 95% CI 1.02--1.08) relative increase in the probability of healing, respectively, with esomeprazole vs alternative PPIs. Also, the authors found that esomeprazole conferred an 8% (relative risk 1.08; 95% CI 1.05--1.11) relative increase in the probability of GERD symptom relief at 4 weeks ([@b16]). In this meta-analysis, the calculated numbers needed to treat (NNT) by Los Angeles grade of erosive esophagitis (grades A--D) were 50, 33, 14, and 8 ([@b16]). This suggests that the benefit of esomeprazole might be important in more severe erosive disease as indicated by the decreasing NNTs with increasing Los Angeles grade ([@b16]). It is at the present time not entirely clear if these statistically significant differences are clinically significant.

Maintenance therapy of healed erosive GERD
------------------------------------------

GERD usually relapses once drug therapy is discontinued, with about 80% having erosive GERD relapse after 6--12 months ([@b7]; [@b42]). Thus, many patients with GERD require long-term, possibly life-long, PPI therapy ([@b42]). However, a recent study on discontinuation of PPIs in long-term users found that 20% of GERD patients were able to discontinue their PPIs without development of symptoms ([@b3]).

Two double-blind, randomized studies have shown superiority of esomeprazole 40 mg, 20 mg, or 10 mg od to placebo in maintenance therapy of healed erosive GERD ([@b24]; [@b57]). The primary endpoint of both studies was endoscopically maintained healing 6 months after inclusion. In one of these, 375 patients with endoscopically healed esophagitis were randomized to receive esomeprazole 40 mg, 20 mg, 10 mg, or placebo od ([@b57]). After 6 months, significantly (p \< 0.001) more patients remained healed with esomeprazole 40 mg (87.9%), 20 mg (78.7%), or 10 mg (54.2%) than with placebo (29.1%) at endoscopy ([@b57]). In the other placebo-controlled study, 318 patients with endoscopically confirmed healing of erosive GERD were randomized to receive esomeprazole 40 mg, 20 mg, 10 mg, or placebo od ([@b24]). After 6 months, healing was maintained in 93.6% of patients treated with esomeprazole 40 mg, 93.2% treated with esomeprazole 20 mg, and 57.1% treated with esomeprazole 10 mg; p \< 0.001 vs 29.1% treated with placebo ([@b24]). Both of these studies reported that patients treated with esomeprazole had less severe heartburn than those treated with placebo. However, symptom maintenance data from these studies should be interpreted with caution as only those patients who maintained healing at the previous visit continued to the subsequent visits during the 6-month study period ([@b24]; [@b57]).

Three clinical trials have compared esomeprazole with other PPIs as a maintenance therapy in GERD patients with healed erosive esophagitis ([Table 3](#tbl3){ref-type="table"}). Studies reported in [Table 3](#tbl3){ref-type="table"} had a similar double-blind, randomized design and they included intention-to-treat analyses of endoscopy and symptom maintenance rates. Also, all three studies included patients who had endoscopy-confirmed healing of their erosive GERD at baseline and follow-up endoscopy was performed at 3 and 6 months. The primary endpoint was endoscopic and symptom maintenance at 6 months. Secondary endpoints were separate endoscopic and symptom maintenance rates at 6 months ([@b36]; [@b33]; [@b8]). No comparative studies of esomeprazole vs omeprazole or rabeprazole in maintenance therapy of healed erosive GERD could be found.

###### 

Randomized trials evaluating the efficacy of esomeprazole vs other PPIs in combined endoscopic and symptomatic maintenance of healed erosive GERD

  Reference   Study design               Number of patients   PPIs compared         Maintenance rates at 6 months
  ----------- -------------------------- -------------------- --------------------- -------------------------------
  [@b36]      Double-blind, randomized   1224                 Eso20 vs lan15 od     83 % vs 74%, p \< 0.0001
  [@b33]      Double-blind, randomized   2766                 Eso20 vs panto20 od   87% vs 74.9%, p \< 0.0001
  [@b8]       Double-blind, randomized   1026                 Eso20 vs lan15 od     84.5% vs 75.9%, p \< 0.0007

**Notes:**No randomized studies comparing esomeprazole with rabeprazole or omeprazole as to healing erosive GERD were found.

**Abbreviations:**Eso, esomeprazole; lan, lansoprazole; panto, pantoprazole; PPI, proton-pump inhibitor.

All three studies showed superiority of esomeprazole 20 mg to lansoprazole 15 mg or pantoprazole 20 mg od in the primary endpoint ([Table 3](#tbl3){ref-type="table"}). Furthermore, these studies showed superiority of esomeprazole 20 mg to lansoprazole 15 mg (endoscopic maintenance rate: 84% vs 76%, p \< 0.0002 ([@b36]); 84.5% vs 75.9%, p \< 0.0001 ([@b8]) or pantoprazole 20 mg (88.1% vs 76.6%, p \< 0.0001 ([@b33])) od in maintaining endoscopic remission at 6 months. As regards maintenance of symptomatic remission only, one of these studies reported that esomeprazole 20 mg was more effective than lansoprazole 15 mg od (symptomatic remission maintenance rate: 78% vs 71%, p \< 0.001 ([@b36])) and another that esomeprazole 20 mg was more effective than pantoprazole 20 mg od (94.5% vs 90.5%, p \< 0.0001 ([@b33])). However, the third study could not show any statistically significant difference between esomeprazole and lansoprazole 15 mg od in maintaining symptomatic remission (76.4% vs 73%, p \> 0.05) ([@b8]). Lastly, studies comparing esomeprazole with lansoprazole showed that esomeprazole had consistently higher remission maintenance rates when patients were stratified according to initial severity of erosive GERD ([@b36]; [@b8]). However, the study comparing esomeprazole 20 mg with pantoprazole 20 mg od reported that although esomeprazole had higher remission maintenance remission rates in patients with erosive GERD Los Angeles A--C, differences were not significant in patients with Los Angeles D ([@b33]).

Although these data indicate superiority of esomeprazole compared with lansoprazole or pantoprazole in maintenance therapy of healed erosive GERD, there is a need for new clinical trials comparing esomeprazole with omeprazole and rabeprazole before definite conclusions can be drawn.

Non-erosive GERD
================

Patients with NERD may exhibit similar symptom severity to those with erosive GERD but as many as half of them may have a normal esophageal pH testing demonstrating pH values within the normal range of healthy subjects ([@b39]). Although PPIs have been shown to be effective in patients with NERD ([@b37]), symptom improvement is lower compared with patients with erosive GERD ([@b39]).

Three papers on clinical trials comparing continuous esomeprazole with other PPIs as therapy in NERD patients were identified. They all had a similar double-blind, randomized design, patients had a normal baseline endoscopy, intention-to-treat analysis of data was performed, and study duration was 4 weeks ([@b1]; [@b12]; [@b43]). No study comparing continuous esomeprazole with lansoprazole therapy in NERD was identified.

In one of these papers ([@b1]), three studies were reported comparing A (n = 1282) esomeprazole 40 mg, esomeprazole 20 mg, or omeprazole 20 mg od; B (n = 693) esomeprazole 40 mg or omeprazole 20 mg od; and C (n = 670) esomeprazole 20 mg or omeprazole 20 mg od. Resolution of heartburn at 4 weeks (no heartburn symptoms during the last 7 days) was achieved in similar proportions of patients in each treatment arm in study A (esomeprazole 40 mg, 56.7%; esomeprazole 20 mg, 60.5%; omeprazole 20 mg, 58.1%), study B (esomeprazole 40 mg 70.3%; omeprazole 20 mg 67.9%), and study C (esomeprazole 20 mg 61.9%; omeprazole 20 mg, 59.6%). There were no significant differences between treatment groups within each study. Thus, not only were esomeprazole and omeprazole treatments comparable but also esomeprazole 40 mg and esomeprazole 20 mg od did not yield significantly different results after 4 weeks in patients with NERD ([@b1]).

Another clinical trial performed in Asian patients (n = 127) with NERD compared esomeprazole 20 mg with rabeprazole 10 mg od ([@b12]). After 4 weeks of treatment the two PPIs were comparable for the primary endpoint of the study, ie, the time needed to achieve a 24-hour symptom-free interval for heartburn (esomeprazole 20 mg, 9 days; rabeprazole 10 mg, 8.5 days; p \> 0.05) and regurgitation (esomeprazole 20 mg, 7.5 days; rabeprazole 10 mg, 6 days; p \> 0.05). The authors reported that the two therapies were also comparable in terms of patient's global evaluation, with 87.9% of patients on esomeprazole and 96% of patients on rabeprazole reporting that symptoms improved (p \> 0.05) ([@b12]).

A third study comparing esomeprazole 20 mg with pantoprazole 20 mg od for the treatment of NERD patients (n = 529) reported that the median time to first symptom relief was 2.0 days for both PPIs ([@b43]). This study was designed to show non-inferiority of the pantoprazole group compared with the esomeprazole group with a significance level of 5%. The Hodges-Lehmann estimator and the one-sided 95% CI according to Moses were calculated. Non-inferiority was concluded if the lower boundary of the 95% CI was greater than −2 days, as the difference of 2 days was considered clinically significant. For the primary endpoint variable (time to first symptom relief), the one-sided 95% CI was zero (0.00). Considering that the non-inferiority margin was set at −2 days, the lower boundary of the 95% CI (0.00) was higher. Thus, the authors concluded that pantoprazole was as effective as esomeprazole for time to first symptom relief. Similar results were obtained for time to sustained symptom relief ([@b43]).

Although no trial comparing continuous esomeprazole with lansoprazole therapy was identified, in a recently published single-blind study esomeprazole 20 mg on demand was compared with lansoprazole 15 mg od ([@b55]). Seven hundred and seventy-four patients with NERD who achieved complete resolution of heartburn after short term (2--4 weeks) treatment with esomeprazole 20 mg were randomized to receive either esomeprazole 20 mg on demand or lansoprazole 15 mg continuous daily treatment. Significantly more patients were willing to continue taking esomeprazole on demand than lansoprazole od after 6 months (93% vs 88%, p = 0.02). The authors concluded that esomeprazole 20 mg on demand was more acceptable to NERD patients compared with lansoprazole 15 mg od ([@b55]). However, it should be pointed out that this was a single-blind trial (due to its nature) and that it may hardly constitute evidence of superiority of esomeprazole to lansoprazole in NERD, as the two PPIs were administered in different ways. Therefore, results of this study may merely reflect patient preference for on-demand therapy.

Long-term (6 month) on-demand esomeprazole treatment has been reported to be superior to placebo in the therapy of patients with NERD as assessed in two double-blind, randomized clinical trials in which NERD patients were included after achieving complete resolution of heartburn after short-term esomeprazole or omeprazole treatment ([@b53], [@b54]). In one of these, 342 patients with NERD were randomized to receive either esomeprazole 20 mg or placebo on demand for 6 months ([@b53]). The proportion of patients who discontinued treatment due to insufficient control of heartburn was significantly higher among placebo compared to esomeprazole recipients (51% vs 14%, p \< 0.0001). In the second study, 721 patients were randomized to esomeprazole 20 mg, 40 mg, or placebo on demand for 6 months ([@b54]). During this period, 42% of placebo recipients discontinued treatment due to unwillingness to continue, compared with 8% and 11% of esomeprazole 20 mg and 40 mg recipients, respectively. Although a p \< 0.0001 was calculated for comparisons between either esomeprazole group and placebo, no significant difference was observed between the esomeprazole treatment groups (p = 0.15). Thus the authors concluded that esomeprazole 20 mg is superior to placebo for on-demand treatment of NERD and that a higher esomeprazole dose does not confer additional clinical benefit. However, it should be pointed out that almost 60% (58%) of patients who were randomized to placebo were willing to continue treatment ([@b54]). These results clearly indicate that not all patients who have had resolution of symptoms after 4 weeks of PPI therapy will need continuous treatment in the future.

Esomeprazole in the treatment of GERD and health-related quality of life
========================================================================

There has been increasing interest in evaluating patient- reported outcomes such as health-related QoL. It is widely accepted that patients with GERD experience decrements in health-related QoL compared with the general population ([@b46]; [@b45]; [@b44]), similar to those seen in patients with other chronic diseases ([@b32]). Patients with non-erosive GERD, erosive GERD, and Barrett's esophagus have been reported to have similar impairment in health-related QoL ([@b32]). Successful treatment of GERD with symptom resolution results in improvements in health-related QoL ([@b46]; [@b45]).

In a recent large uncontrolled study assessing the impact of GERD on QoL as well as the effect of acute esomeprazole treatment on QoL, indices were evaluated ([@b32]). A total of 6215 patients prospectively diagnosed with GERD underwent endoscopy and received treatment with esomeprazole 20 mg od (patients with NERD) or 40 mg od (erosive GERD). Symptoms and health-related QoL were evaluated at baseline and after 2 weeks of treatment by means of validated questionnaires ([@b32]). At baseline, QoL in GERD patients was lower than in the general population but within 2 weeks, after treatment with esomeprazole, both symptoms and QoL improved in all subscales ([@b32]).

Recently a large randomized study evaluated the long-term effect of two maintenance treatment modalities with esomeprazole in non-erosive and mild erosive GERD ([@b44]). Altogether, 6017 patients with GERD symptoms (max grade I esophagitis according to Savary-Miller's classification at baseline endoscopy) received acute treatment with esomeprazole 40 mg od for 4 weeks. If successfully treated, they were randomized to either esomeprazole 20 mg od or esomeprazole 20 mg on demand for 6 months. Health-related QoL was measured with validated questionnaires at baseline as well as at the start and conclusion of the maintenance period. At baseline, GERD patients had profound reductions in QoL indices but after acute esomeprazole treatment for 4 weeks all QoL dimensions showed statistically significant (p \< 0.0001) improvements. A statistically significant difference in QoL scores was registered at the end of the maintenance phase in favor of the continuous regimen ([@b44]).

Lastly, a study from Norway assessed the efficacy of three treatment regimens in improving health-related QoL in patients with GERD symptoms ([@b17]). Following a 4-week symptom-control phase (esomeprazole 40 mg od), patients were randomized to 6 months' esomeprazole 20 mg od continuously (n = 658), esomeprazole 20 mg od on-demand (n = 634), or ranitidine 150 mg bd continuously (n = 610). Health-related QoL was assessed by means of validated questionnaires at baseline as well as at the start and conclusion of the maintenance period. Esomeprazole 40 mg od improved QoL during the acute symptom-control phase. At 6 months, both esomeprazole regimens were more effective than ranitidine in all dimensions of QoL (p \< 0.0001). However, esomeprazole 20 mg od continuously maintained QoL better than esomeprazole on demand and was associated with greater patient satisfaction ([@b17]).

Thus, there are data to support that esomeprazole treatment is associated with improvement in health-related QoL indices in patients with GERD, at least compared with ranitidine. However, double-blind, randomized studies comparing the effect of esomeprazole with that of other PPIs on QoL indices at GERD treatment are lacking.

Conclusion
==========

In patients with gastroesophageal reflux disease, standard doses of esomeprazole maintain intragastric pH above 4 for significantly longer periods compared with standard doses of other PPIs after 5 days of treatment. Despite some controversy, data from clinical trials and meta-analyses indicate that esomeprazole 40 mg od for up to 8 weeks provides higher rates of healing of erosive GERD and a greater proportion of patients with sustained resolution of heartburn, than omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od. Esomeprazole 20 mg od has also been shown to be more effective in maintaining healing of erosive GERD compared to lansoprazole 15 mg od or pantoprazole 20 mg od. However, it is not clear whether these statistically significant differences are of major clinical importance. Comparative efficacy studies are also lacking between esomeprazole and rabeprazole in healing and maintenance of healed erosive GERD as well as between esomeprazole and omeprazole or rabeprazole in maintenance of healed erosive GERD. Esomeprazole 20 mg od is superior to placebo for treatment of NERD but clinical trials have not shown any significant differences in efficacy between esomeprazole 20 mg and omeprazole 20 mg or pantoprazole 20 mg od in this group of patients. No comparative data between esomeprazole and lansoprazole or rabeprazole in NERD could be identified. Lastly, although esomeprazole treatment in GERD has been reported to result in improvement of health-related QoL indices, no clinical trials have evaluated the possible differential effects of different PPIs on QoL in patients treated for GERD.

GERD

:   Gastro-esophageal reflux disease

NERD

:   non-erosive reflux disease

PPIs

:   proton pump inhibitors

QoL

:   quality of life

CI

:   confidence interval
